Compare · BSX vs NVST
BSX vs NVST
Side-by-side comparison of Boston Scientific Corporation (BSX) and Envista Holdings Corporation (NVST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NVST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 16.9x NVST ($3.77B).
- BSX has been more active in the news (5 items in the past 4 weeks vs 2 for NVST).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Envista Holdings Corporation
- Price
- -
- -
- Market cap
- $63.97B
- $3.77B
- 1M return
- -
- -3.27%
- 1Y return
- -
- +16.15%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest NVST
- Envista downgraded by Robert W. Baird with a new price target
- Envista Schedules Third Quarter 2026 Earnings Call
- Envista Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Envista Announces Participation in Baird 2026 Global Healthcare Conference
- Envista upgraded by Analyst with a new price target
- President, Orthodontics Acurio Veronica covered exercise/tax liability with 7,710 shares, decreasing direct ownership by 14% to 48,806 units (SEC Form 4) (tax withholding)
- President, Diagnostics Befidi Robert covered exercise/tax liability with 5,147 shares, decreasing direct ownership by 10% to 45,785 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Hammes Eric D. covered exercise/tax liability with 10,885 shares, decreasing direct ownership by 10% to 99,913 units (SEC Form 4) (tax liability)
- President, Nobel Biocare Nilsson Stefan covered exercise/tax liability with 804 shares, decreasing direct ownership by 1% to 61,560 units (SEC Form 4) (withholding tax)
- SVP, Strategy & Bus. Dev. Reis Mischa sold $220,000 worth of shares (8,000 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 27,321 units (SEC Form 4)